about
Variation in healthcare services for specialist genetic testing and implications for planning genetic services: the example of inherited retinal dystrophy in the English NHS.Multivariate meta-analysis of mixed outcomes: a Bayesian approach.Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis.Exploring the mechanisms of change in the chronic disease self-management programme: secondary analysis of data from a randomised controlled trial.Effect of a national primary care pay for performance scheme on emergency hospital admissions for ambulatory care sensitive conditions: controlled longitudinal studyParity, time since last live birth and long-term functional outcome: a study of women participating in the Norfolk Arthritis RegisterPrevalence of autistic spectrum disorders in Lothian, Scotland: an estimate using the "capture-recapture" technique.Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs--results of the British Rheumatoid Outcome Study Group randomized controlled clinicAssociation of functional outcome with both personal- and area-level socioeconomic inequalities in patients with inflammatory polyarthritisRates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.Attitude to health risk in the Canadian population: a cross-sectional survey.Health state utility values: a description of their development and application for rheumatic diseases.The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritisUse of Bayesian multivariate meta-analysis to estimate the HAQ for mapping onto the EQ-5D questionnaire in rheumatoid arthritis.The OMERACT Initiative. Towards a reference approach to derive QALY for economic evaluations in rheumatology.Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.Risk as an attribute in discrete choice experiments: a systematic review of the literature.Economics of stratified medicine in rheumatoid arthritis.How important is mode of administration in treatments for rheumatic diseases and related conditions?Do patients and health care providers have discordant preferences about which aspects of treatments matter most? Evidence from a systematic review of discrete choice experiments.The impact of medication reviews by community pharmacists.Incentives in Rheumatology: the Potential Contribution of Physician Responses to Financial Incentives, Public Reporting, and Treatment Guidelines to Health Care Sustainability.Using Survival Analysis to Improve Estimates of Life Year Gains in Policy Evaluations.Potential cost-effectiveness for using patient decision aids to guide osteoporosis treatment.Communicating Uncertainty in Benefits and Harms: A Review of Patient Decision Support Interventions.Delivery of paediatric rheumatology care in the UK--the projected shortfall.Does Introducing Imprecision around Probabilities for Benefit and Harm Influence the Way People Value Treatments?The Impact of Waiting Time on Health Gains from Surgery: Evidence from a National Patient-reported Outcome Dataset.Providing an extended use of an otological-specific outcome instrument to derive cost-effectiveness estimates of treatment.Mapping the disease-specific LupusQoL to the SF-6D.Same question, different answers: a comparison of global health assessments using visual analogue scales.OMERACT 10 Patient Perspective Virtual Campus: valuing health; measuring outcomes in rheumatoid arthritis fatigue, RA sleep, arthroplasty, and systemic sclerosis; and clinical significance of changes in health.A secondary analysis of the moderating effects of depression and multimorbidity on the effectiveness of a chronic disease self-management programme.Construct and criterion validity of the short form-6D utility measure in patients with systemic lupus erythematosus.Health-related quality of life, smoking and carotid atherosclerosis in white British women with systemic lupus erythematosus.Societal preferences for rheumatoid arthritis treatments: evidence from a discrete choice experiment.Why do patients with inflammatory arthritis often score states "worse than death" on the EQ-5D? An Investigation of the EQ-5D classification system.The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis.Patient Satisfaction and Costs of Multidisciplinary Models of Care in Rheumatology: a Review of the Recent Literature.Valuing Health for Clinical and Economic Decisions: Directions Relevant for Rheumatologists
P50
Q30626900-EC1CD7D0-4161-4717-9197-5126295F062CQ33587615-ED65BA4B-4BB1-4F2F-8FF3-48D4DF7A5105Q33692177-9FCF9F16-1EED-4B7A-9804-3E93360E1D41Q33757327-D3F711E7-DEF6-4EC2-97A7-C4B7F9B62288Q34492715-5E8E95BD-4D8C-410D-8DD5-D65E22D351EEQ35537108-0E323C2D-9D2C-476C-8A73-D4FE2DD1D4E0Q36153730-55F873DB-A905-467B-926A-B7EE1A8CD355Q36303507-829CFCB0-5771-47C7-B1FF-2D808D7E4E0AQ36388001-22365E03-C002-4B79-904E-4E2190758776Q37020532-1D1EF17A-0206-4337-AA1B-2A66D097B09DQ37066921-45D2F20E-9E4F-4E7F-8DAB-F0FCFAF7769CQ37199171-29FF561C-97AA-44B5-B9BE-A8AD96942B4CQ37387224-3BA05D2D-7701-47E0-8825-DD60A4A052B9Q37572857-EF7E3BE3-BF22-443D-962B-FA9A7F05BB08Q37593843-EDCA5774-BDBF-452C-B18D-B684DE567AEFQ38171360-102747C2-D859-4C68-B900-9A7E5B34CC8FQ38190876-250A1C84-D827-4FF9-97F4-72286B5E4ED9Q38264743-B3D7A963-30F6-4194-B168-B15253CBB35CQ38436502-ABB77071-013D-454A-A4D8-14BBACED0CDFQ38682667-160765F2-0223-4E1D-8D3A-D2FAC7948CE6Q38824394-2BFDEF96-4D94-4093-B1F0-916807C80418Q38848203-0D12A765-3175-468A-8C95-935B23E57846Q38852135-2B123863-9D0C-4D4A-A60A-06F641561F7CQ38870159-A9216037-7D72-4E2A-BADB-FB86D44D3421Q39025266-7F9CFBA4-0746-477E-91D3-9BF91A8FB924Q39802162-E41BBCC0-463B-4281-90F5-A5C11153511DQ40610946-0B6EC7A6-EABE-49CB-B2BF-F1745390AE7DQ40899659-ED6234AE-CD17-4BA2-B821-B3CDF6DD139DQ41148587-9AEF9F94-AF8E-428E-A6BC-5D2E17D73DD2Q41687005-3746BB94-4963-4794-BB97-7CB5988C349DQ45041652-A530F445-001E-4A01-B149-19B11594C829Q48290266-651F851B-FD1D-4A56-8442-DB34F5F08CACQ48628108-B37DC7D1-3481-4083-89D0-FBB27CB3781FQ48738926-A6D1E78C-EFB5-4AF0-A82C-6DD36DB5EBE2Q48932993-4185652F-4F3A-43C9-BD2A-3DE8727826CDQ50916784-1EBF2FD7-A217-4307-82B0-EA8047BBE894Q51827038-A883A9FC-B8E4-4A5A-80F7-40FB39FCDDA8Q51923599-AC53FA33-E06F-4E20-8E10-788CDB2D5A36Q52650289-E8627FCE-31D1-49B9-AC6D-6DC21F5B88BDQ57169397-7107E13F-1A57-4703-9A7A-0CAC1004EB37
P50
description
researcher
@en
researcher
@en-gb
հետազոտող
@hy
name
Mark Harrison
@ast
Mark Harrison
@en
Mark Harrison
@en-gb
Mark Harrison
@es
Mark Harrison
@nl
Mark Harrison
@sl
type
label
Mark Harrison
@ast
Mark Harrison
@en
Mark Harrison
@en-gb
Mark Harrison
@es
Mark Harrison
@nl
Mark Harrison
@sl
prefLabel
Mark Harrison
@ast
Mark Harrison
@en
Mark Harrison
@en-gb
Mark Harrison
@es
Mark Harrison
@nl
Mark Harrison
@sl
P106
P21
P31
P496
0000-0002-2115-2447